This theoretical article revives a classical bridging construct, canalization, to describe a new
model of a general factor of psychopathology. To achieve this, we have distinguished …

Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …

Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an
anesthetic, has shown significant promise as a medication with rapid antidepressant …

The discovery of ketamine as a rapid-acting antidepressant spurred significant research to
understand its underlying mechanisms of action and to identify other novel compounds that …

Recent clinical and preclinical evidence suggests that psychedelics and entactogens may
produce both rapid and sustained therapeutic effects across several indications. Currently …

Multiple lines of evidence have implicated brain-derived neurotrophic factor (BDNF) in
treatment-resistant depression (TRD). The aim of this synthesis was to determine the impact …

The discovery of ketamine as a rapid-acting antidepressant led to a new era in the
development of neuropsychiatric therapeutics, one characterized by an antidepressant …

Background A significant proportion of adults with major depressive disorder (MDD) do not
respond to treatments which are currently used in clinical practice such as first-generation …

Background: Clinical trials have demonstrated rapid antidepressant effects with intravenous
(IV) ketamine for major depressive disorder, with relatively less research specifically for …

Introduction Ketamine intravenous therapy (KIT) appears effective for treating depression in
controlled trials testing a short series of infusions. A rapidly proliferating number of clinics …